CINCINNATI, June 17 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced that several of its executives will present on important industry issues at the Drug Information Association (DIA) 45th Annual Meeting June 21-25, 2009, in San Diego, Calif. Kendle experts will address key topics in clinical development, including regulatory issues in portfolio management, pregnancy registries and risk management, and patient recruitment and retention for pregnancy registries.
Wednesday, June 24, 3:30-5 p.m., Room 14B Managing Development Portfolios in a Safety-Heightened Environment William K. Sietsema, PhD Vice President, U.S. Regulatory Consulting and Submissions Thursday, June 25, 8:30-10 a.m. Pregnancy Registries: Perspectives on a Unique Risk Management Tool Deborah Covington, DrPH, MS, Senior Director, Late Phase Laura F. McKain, MD, Medical Director, Registries and Epidemiology, Late Phase Poster Presentation Pregnancy Exposure Registries: Enhancing Recruitment and Retention Deborah Covington, DrPH, MS Senior Director, Late Phase
Kendle at Booth #439
Kendle experts will be available for on-site meetings and to discuss the Company's model for consistent quality execution of Phase I-IV clinical development programs and best practices in the development of strategic customer relationships.
In addition to Phase I-IV clinical development capabilities, the Kendle display also will highlight the Company's continued and recent success in delivering consistent quality and building effective site relationships as validated by independent third-party quantitative research. Kendle recently was named the highest-rated top-five CRO in the 2009 CenterWatch Survey of U.S. Investigative Sites. The Company is the only CRO to have been ranked consistently among the top two providers in the 2009, 2008 and 2007 CenterWatch surveys of U.S. and European investigative sites. In addition, according to the "2009 CRO Quality Benchmarking Report" published by Industry Standard Research (ISR), "Kendle delivers the most consistent quality services" as measured by the "Service Variability Index" (SVI), a measurement of consistency, which researchers at ISR identified as the most significant indicator of quality. Kendle's industry-best score was 12.2 (lower score = less variability, and closer to ideal distribution), while the industry average was 25.1. Kendle rated highest among CROs in the areas of CRA Quality, Consistent Quality Delivery, Meeting Project Timelines and Efficient Site Start-up.
Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the fastest-growing global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.
Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's Web site at www.kendle.com.
|SOURCE Kendle International Inc.|
Copyright©2009 PR Newswire.
All rights reserved